Cognitive Behavioral Therapy Added to Risperidone for Schizophrenia (CBT-BDNF-SCZ)
Effectiveness of Cognitive Behavioral Therapy as Adjunctive Therapy on Cognitive Function and Serum Brain-Derived Neurotrophic Factor Levels in Patients With Schizophrenia Receiving Risperidone Therapy
This study evaluated whether cognitive behavioral therapy (CBT), when added to risperidone treatment, improves cognitive function and serum brain-derived neurotrophic factor (BDNF) levels in patients with schizophrenia. Participants were adults with stable-phase schizophrenia who were receiving risperidone therapy. They were assigned to either a control group receiving risperidone alone or an intervention group receiving risperidone plus 10 weekly CBT sessions.
Cognitive function was assessed using the Indonesian version of the Cognitive Assessment Interview (CAI-Ina). Serum BDNF levels were measured from blood samples using an enzyme-linked immunosorbent assay (ELISA). Measurements were performed at baseline and after 10 weeks. The study was conducted at Rumah Sakit Khusus Daerah Dadi, South Sulawesi, Indonesia.
調査の概要
詳細な説明
Schizophrenia is a chronic psychiatric disorder associated not only with psychotic symptoms but also with persistent cognitive impairment. Cognitive deficits may affect attention, working memory, verbal memory, processing speed, reasoning, problem solving, and social cognition. These impairments can interfere with daily functioning and long-term recovery. Although risperidone is commonly used as an antipsychotic treatment for schizophrenia, its effect on cognitive function may be limited. Cognitive behavioral therapy (CBT) may provide additional benefit by helping patients identify maladaptive beliefs, develop coping strategies, improve insight, and strengthen adaptive behavior.
This study was designed to evaluate the effect of CBT as an adjunctive therapy to risperidone on cognitive function and serum BDNF levels in patients with schizophrenia. BDNF is a neurotrophic factor involved in neuroplasticity, synaptic function, learning, and memory. Lower BDNF levels have been associated with cognitive impairment in schizophrenia. The study assessed whether adding CBT to risperidone therapy was associated with improvement in cognitive function and changes in serum BDNF levels.
This was an interventional, randomized, single-blind, rater-blind study. Participants were patients with stable-phase schizophrenia treated at Rumah Sakit Khusus Daerah Dadi, South Sulawesi, Indonesia. Eligible participants were adults aged 20 to 50 years with schizophrenia diagnosed according to DSM-5 and PPDGJ-III criteria, illness onset of 5 years or less, stable clinical condition, and ongoing risperidone therapy.
Participants were assigned to two groups. The control group received risperidone therapy. The intervention group received risperidone therapy plus CBT. The CBT intervention consisted of 10 sessions delivered once weekly over 10 weeks, with each session lasting approximately 30 minutes. The CBT sessions included engagement and assessment of target problems, cognitive formulation, exploration of appraisals, evaluation of beliefs, gentle reality testing, development of alternative explanations, behavioral experiments, coping strategy enhancement, insight building, relapse prevention, and future planning.
Cognitive function was measured using the Indonesian version of the Cognitive Assessment Interview (CAI-Ina), an interview-based instrument for assessing cognitive function in patients with schizophrenia. Serum BDNF levels were measured from peripheral blood samples using ELISA. Assessments were performed at baseline and at week 10. The main objective was to compare changes in cognitive function and serum BDNF levels between the risperidone-only group and the risperidone plus CBT group.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
South Sulawesi
-
Makassar、South Sulawesi、インドネシア、90113
- Rumah Sakit Khusus Daerah (RSKD) Dadi Provinsi Sulawesi Selatan
-
-
参加基準
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Patients diagnosed with schizophrenia according to DSM-5 and PPDGJ-III criteria.
- Illness onset of schizophrenia ≤ 5 years since the first appearance of symptoms.
- Age 20 to 50 years.
- Clinically stable phase, defined as PANSS score 30 to 60.
- Receiving risperidone therapy at a dose of 4 to 6 mg/day.
- Minimum educational level of senior high school.
- Willing to participate in the study and sign informed consent.
Exclusion Criteria:
- Presence of organic comorbid conditions, such as neurological disorders, severe endocrine or metabolic disorders, chronic liver or kidney disease, or systemic infection, that may affect cognitive function or serum BDNF levels.
- History of substance use before hospital admission, except caffeine and nicotine.
- Use of anti-inflammatory drugs, antibiotics, or antioxidant medications.
- Intellectual disability or mental retardation.
- Unwilling to attend cognitive behavioral therapy sessions.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ：Control Group
Participants received risperidone therapy without cognitive behavioral therapy.
|
Risperidone was administered as antipsychotic therapy for patients with schizophrenia.
Participants in both study groups received risperidone therapy according to the study protocol.
|
|
実験的：Intervention Group
Participants received risperidone therapy plus 10 weekly sessions of cognitive behavioral therapy over 10 weeks.
Each CBT session lasted approximately 30 minutes.
|
Risperidone was administered as antipsychotic therapy for patients with schizophrenia.
Participants in both study groups received risperidone therapy according to the study protocol.
Cognitive behavioral therapy was delivered as an adjunctive intervention to risperidone therapy.
The intervention consisted of 10 weekly sessions over 10 weeks, with each session lasting approximately 30 minutes.
Sessions included engagement, cognitive formulation, appraisal exploration, belief evaluation, gentle reality testing, alternative explanations, behavioral experiments, coping strategy enhancement, insight building, relapse prevention, and future planning.
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Cognitive Function Assessed by CAI-Ina Total Score
時間枠：Baseline and week 10
|
Cognitive function was assessed using the Indonesian version of the Cognitive Assessment Interview (CAI-Ina).
The CAI-Ina evaluates cognitive function in patients with schizophrenia, including processing speed, attention, working memory, verbal memory, reasoning and problem solving, and social cognition.
Higher scores indicate greater cognitive impairment.
The outcome was the change in total CAI-Ina score from baseline to week 10.
|
Baseline and week 10
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Serum Brain-Derived Neurotrophic Factor Level
時間枠：Baseline and week 10
|
Serum brain-derived neurotrophic factor (BDNF) level was measured from peripheral blood samples using enzyme-linked immunosorbent assay (ELISA).
The outcome was the change in serum BDNF level from baseline to week 10.
Values were reported in pg/mL.
|
Baseline and week 10
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Maya Angela Lisal, Medical Doctor、Hasanuddin University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- UH25090757
- 807/UN4.6.4.5.31/PP36/2025 (その他の識別子：Hasanuddin University Research Ethics Committee)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。